Keyphrases
Dual Inhibition
100%
Lymphoma Cells
100%
Cutaneous T-cell Lymphoma
100%
Mammalian Target of Rapamycin (mTOR)
100%
Induced Apoptosis
100%
Rapamycin
46%
Eukaryotic Translation Initiation Factor 4E (eIF4E)
23%
Cell Growth
23%
Malignancy
15%
Cell Survival
15%
4E-binding Protein 1
15%
Mnk Inhibitors
15%
Raptor
7%
Cell Apoptosis
7%
Short-term Treatment
7%
Non-toxic Inhibitor
7%
MNK Kinases
7%
Apoptotic Effect
7%
Phosphorylation
7%
Rapamycin Inhibitor
7%
40S Ribosomal Subunit
7%
Signaling Pathway
7%
Poor Prognosis
7%
Key Cells
7%
Response to Therapy
7%
MNK1
7%
Lack of Response
7%
MNK2
7%
Clinical Efficacy
7%
Cell Function
7%
Cell Surface Display
7%
Cell-derived
7%
Neuroscience
T Cell
100%
NADH Dehydrogenase (Ubiquinone)
100%
Programmed Cell Death
100%
Sirolimus
58%
Cell Growth
25%
Cell Survival
16%
Cell Function
8%
Kinase
8%
Mammalian Target of Rapamycin
8%
Cell Signaling
8%
Biochemistry, Genetics and Molecular Biology
Programmed Cell Death
100%
Mammalian Target of Rapamycin
100%
T Cell
100%
Cell Growth
25%
Binding Protein
16%
Synapsin I
16%
Cell Survival
16%
Kinase
8%
Cell Function
8%
Eukaryotic Initiation Factor
8%
Phosphotransferase
8%
Mechanistic Target of Rapamycin
8%
Pharmacology, Toxicology and Pharmaceutical Science
Cutaneous T Cell Lymphoma
100%
Reduced Nicotinamide Adenine Dinucleotide Dehydrogenase (Ubiquinone)
100%
Rapamycin
58%
Initiation Factor 4E Binding Protein 1
16%
Protein S6
8%
Phosphotransferase
8%
Mammalian Target of Rapamycin
8%